dc.contributor
Institut Català de la Salut
dc.contributor
[Gustà MF] Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain. [Edel MJ] Hospital Clínic de Barcelona, Servei Immunologia-IDIBAPS, Barcelona, Spain. Unit of Anatomy and Embryology, Universitat Autònoma de Barcelona, Faculty of Medicine, Barcelona, Spain. University of Western Australia, Faculty of Medicine, Discipline of Medical Sciences and Genetics, School of Biomedical Sciences, Perth, WA, Australia. [Salazar VA] Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. [Alvarez-Palomo B] Banc de Sang i Teixits, Cell Therapy Service, Barcelona, Spain. [Juan M] Hospital Clínic de Barcelona, Servei Immunologia-IDIBAPS, Barcelona, Spain. [Broggini M] IRCCS‐Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy. [Puntes V] Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Freixanet Gusta, Muriel
dc.contributor.author
Edel, Michael
dc.contributor.author
Salazar, Vivian Angélica
dc.contributor.author
Alvarez-Palomo, Belén
dc.contributor.author
Juan, Manel
dc.contributor.author
BROGGINI, MASSIMO
dc.contributor.author
Franco Puntes, Victor
dc.date.accessioned
2025-10-25T08:54:05Z
dc.date.available
2025-10-25T08:54:05Z
dc.date.issued
2023-06-06T07:44:38Z
dc.date.issued
2023-06-06T07:44:38Z
dc.date.issued
2023-05-09
dc.identifier
Gustà MF, Edel MJ, Salazar VA, Alvarez-Palomo B, Juan M, Broggini M, et al. Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles. Front Immunol. 2023 May 9;14:1128582.
dc.identifier
https://hdl.handle.net/11351/9659
dc.identifier
10.3389/fimmu.2023.1128582
dc.identifier.uri
http://hdl.handle.net/11351/9659
dc.description.abstract
Gene therapeutics; Gold nanoparticles; Safety
dc.description.abstract
Terapia génica; Nanopartículas de oro; Seguridad
dc.description.abstract
Teràpia gènica; Nanopartícules d'or; Seguretat
dc.description.abstract
Introduction: Gene therapy holds promise to cure various diseases at the fundamental level. For that, efficient carriers are needed for successful gene delivery. Synthetic ‘non-viral’ vectors, as cationic polymers, are quickly gaining popularity as efficient vectors for transmitting genes. However, they suffer from high toxicity associated with the permeation and poration of the cell membrane. This toxic aspect can be eliminated by nanoconjugation. Still, results suggest that optimising the oligonucleotide complexation, ultimately determined by the size and charge of the nanovector, is not the only barrier to efficient gene delivery.
Methods: We herein develop a comprehensive nanovector catalogue comprising different sizes of Au NPs functionalized with two different cationic molecules and further loaded with mRNA for its delivery inside the cell.
Results and Discussion: Tested nanovectors showed safe and sustained transfection efficiencies over 7 days, where 50 nm Au NPs displayed the highest transfection rates. Remarkably, protein expression was increased when nanovector transfection was performed combined with chloroquine. Cytotoxicity and risk assessment demonstrated that nanovectors are safe, ascribed to lesser cellular damage due to their internalization and delivery via endocytosis. Obtained results may pave the way to design advanced and efficient gene therapies for safely transferring oligonucleotides.
dc.description.abstract
We acknowledge financial support from the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU) (RTI2018-099965-B-I00, AEI/FEDER,UE) proyectos de I+D+i de programación conjunta internacional MCIN/AEI (CONCORD, PCI2019-103436) cofunded by the European Union and Generalitat de Catalunya (2017-SGR-1431). ICN2 is supported by the Severo Ochoa program from Spanish MINECO (SEV-2017-0706) and is funded by the CERCA Programme/Generalitat de Catalunya.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Frontiers in Immunology;14
dc.relation
https://doi.org/10.3389/fimmu.2023.1128582
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Nanopartícules
dc.subject
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Endocytosis
dc.subject
TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures::Nanoparticles::Metal Nanoparticles
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Messenger
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Gene Transfer Techniques::Transfection
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::endocitosis
dc.subject
TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::productos manufacturados::nanoestructuras::nanopartículas::nanopartículas metálicas
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ARN::ARN mensajero
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::técnicas de transferencia génica::transfección
dc.title
Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion